Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The level of zero healthA medical medical company, a female institution aimed at opening a new floor by developing an ongoing hormone monitoring device, which closed a $ 6.9 million financing round before the seeds, although it is slightly more than a year. You want to start to get rid of the need to withdraw gaseous blood and support research that may lead to new treatments for the conditions associated with hormone imbalances or even new health care innovations, such as individual doses of hormone -based birth control.
“One of our investors told us that there are companies that build basic technologies and there are companies that build covers about this technology; the co -founder and CEO of Ula Russamova, and it has been discussing the company’s development last time ago Last fall When they presented on the stage in Techcrunch, they were disrupted as part of the start -up battlefield.
“The goal is to create a fully new market of this, right? The same way that CGMS did (continuous glucose screens). They literally, from nothing, created billions of dollars in a market.” “This, by defining it, the category of completely new products – we hope you will inspire people to use the device and data to create many companies in addition to that and the impact of ripples in the next few decades.”
Step -by -step
The construction of a completely new product category may take time for any strip. A factor in this is a startup for devices, and a preliminary medical device, it is clear that zero zero will not be able to provide a model in how to monitor hormones overnight.
That is why the team is also working on a product to use monochromatic (in the image above in the initial model model), which they hope to erase it to use medical prescriptions next year-to support the chopped hormone test associated with medical use such as fertility (IVF) and low testosterone hormone (TRT).
The current initial model, which can be worn, has small needles that allow it to take samples under the skin to discover quantities of hormones.
This is a step towards monitoring hormones that can be worn, and ultimately hope to submit to the market – preliminaryly scheduled for 2028 – is able to withdraw a continuous scale for things such as progesterone, estrogen and testosterone from the interstitial fluid of the younger. (This is a fluuma that fills the areas surrounding the cells, and works as a medium between the blood plasma and cells – thus can also be detected of biochemical compounds in the blood in the interstitial fluid.)
A continuous hormone monitoring device – or, instead, the data you pick up – can play a transformative role in promoting the scientific understanding of hormones that hormones play in human biology – such as CGMS has transformed diabetes management (And more by side).
But the level of zero health is also building business-initially B2B, aims to sell technology in the networks of health care providers-so the founders work on the paths of developing double products to shorten the time to the market and the gap bridge between the Big Bang Mission and what is currently possible.
“We believe that we have this source of truth from which we can benefit from – which is the intellectual liquid,” Restamova told Techcrunch. “We believe that there is an instant product that is shorter, here we must launch first.
“The idea is that the continuing (hormone monitoring) … is the Holy Just – and this is the future – because it is logical, in some way that without contact again, you can put it, and you can get really consistent measurements. But we also understand that, today, we need To enter the market in a way that we do not try to change the protocol-and we do not have a seven-year research issue.
The initial model of measurements throughout the day can be worn when wearing-extracting a series of data points with the aim of “providing value immediately” for use uses such as artificial insemination, as women may need multiple blood clouds to monitor hormone levels.
Rustamova says that the team hopes to conclude clinical experiences and secure a permit to correct intermittent monitoring of one use next year-with approval from the American organizer, FDA, and a CE mark to allow them to sell in European health care markets (it says they are not sure of what might It comes first).
“We hope, this year, we want to show a level of connection (between hormones levels can discover wearable correction and levels that were discovered by withdrawing blood)-and this is the promise that I want to present with the money classified before the seeds,” she adds.
Irene Jia, the co -founder, tells us that the team’s goal is to be able to show 90 %+ association with what the correction can pick up compared to measuring hormone levels by withdrawing blood.
Risks for a reward
Although later-when we discuss the delay between blood-based readings and detection of interstitial fluid-Rusamova to emphasize the difference in medical risks between CGMS and hormone monitoring. She notes that the risk of a person with diabetes (i.e., if glucose readings are delayed or likely to be very high, while monitoring of hormones is not usually those high risks.
“For glucose, you have possible fatal consequences to give a wrong reading or have this delay … (but when it comes to hormone monitoring), the risk of no slight deviation or a kind of association is not narrow.” “It is clear that we will try to link as much as possible – but … there is a risk profile completely different here.” She also indicated that the first CGMS in the market had more relationship with blood readings more than these devices now.
The suggestion is that the team’s goal is to continue to raise the tape on the accuracy. Which – perhaps – hints to the reason that investors were keen to consolidate in the early round of this Medtech start – with potential rewards against the risks that are granted in a positive direction.
The other – undoubtedly – a useful factor here is that the health of the level is zero not only focuses on the health issues of women; Male hormones monitor is an essential part of the initial action plan. (It is still the case that most technology investors are still men putting bets on solving problems that talk about their interests.)
The first -level financing round at the European VC has led, Redalpine. Hax (SOSV), businessman first (EF) and industry experts also contributed to the tour – where SOSV previously accepted the start of the Deeptech/Hardware Hax Accessor, and Rustamova was also an EF.
“We have done this for blood pressure and we will do so again for hormones. Continuous hormone measurement is one of the sacred depression of diagnoses, and as basic scientific transformations for engineering, we cannot be More enthusiastic health support in their mission to convert hormonal tracking with the new biological sensor – the new way to the era of personal health management.